TLSI TriSalus Life Sciences, Inc. Insider Trading

Director Wahlstrom buys 60,000 TLSI shares at $2.53; holdings up 68.5% to 147.6K, stock -61.9% from 52-week high, but 3 prior same-ticker buys showed 100% well-timed at 90-day horizon.

Wahlstrom Mats, a director of TriSalus Life Sciences, purchased 60,000 shares at $2.53 on 2026-05-15 (total value $151,800.00), expanding his holdings by 68.5% to 147.6K shares. This purchase arrives after a sharp equity price decline: the stock is -61.9% from its 52-week high of $7.95 and down -34.8% in the past 30 days. The timing signal, however, appears instructive: across his 3 prior open-market transactions at TLSI (November 2024), Wahlstrom's buys exhibited a 100% well-timed rate at the 90-day horizon, with subsequent returns ranging from +25.7% to +36.8%, despite negative 30-day returns (-2.6% to -11.0%) on those same trades. This pattern suggests Wahlstrom has historically purchased when TLSI shares were depressed in the near term yet recovered materially within 90 days. Underlying fundamentals show the company posted $8.9M revenue and $1.5M net income last quarter, with +53.4% annual revenue growth, though it remains unprofitable on a full-year basis. Investors should monitor whether this 60,000-share accumulation follows the same rebound trajectory Wahlstrom's prior three purchases at this ticker have exhibited.

Director Stansky buys 610,000 shares at $2.50 for $1,525,000 at TLSI; stock down -61.9% from 52-week high, 2 prior buys at this ticker showed 0% 90-day win rate.

Director Michael P Stansky purchased 610,000 shares across 2 separate transactions on 2026-05-15 at $2.50 per share for a total of $1,525,000.00, increasing his post-transaction holdings to 399,698 shares. The purchase price of $2.50 sits well below the current price of $3.03 and dramatically below the 52-week high of $7.95, with the stock currently -61.9% from its peak and down -34.8% over 30 days. Critically, Stansky's same-ticker history at TLSI shows 2 prior buys on 2026-02-23, both yielding -34.6% average 90-day returns with a 0% win rate at the 90-day mark—a pattern of unsuccessful timing on this specific stock that provides context for evaluating this latest accumulation despite the company's recent positive fundamentals (53.4% annual revenue growth, $1.5M net income latest quarter).

CEO Mary T Szela buys 39,682 shares at $2.59; stock down 34.8% in 30 days, -61.9% from 52-week high.

CEO Mary T Szela purchased 39,682 shares at $2.59 on 2026-05-15, increasing her holding to 1,065,215 shares. The stock has declined 34.8% over the past 30 days and trades 61.9% below its 52-week high of $7.95. At TLSI specifically, Szela's 5 prior buy trades showed mixed near-term results: 3 of 5 achieved positive 90-day returns. Her cross-ticker track record shows 9 prior buys with an average 90-day return of -9.6% and a 90d win rate of 33.33%. The company reported latest-quarter revenue of $8,899,000 and net income of $1,539,000, though it was unprofitable over its most recent full fiscal year. Two other insiders also bought within the past 14 days, creating a cluster buy pattern during a period of significant stock price weakness.

CFO Patience David buys 7,100 shares of TLSI at $2.43; stock down -34.8% in 30 days as cluster buy emerges.

Patience David, CFO of TriSalus Life Sciences, purchased 7,100 shares at $2.43 on 2026-05-15, increasing holdings to 275,757 shares. The timing is notable: the stock has declined -34.8% over the past 30 days and -36.5% over 90 days, trading at $3.03 (down -61.9% from its 52-week high of $7.95). His prior open-market buy at this ticker on 2026-02-23 resulted in a -34.6% 90-day return, and his cross-ticker track record shows zero wins from one prior buy (avg 90d return -34.6%). The transaction occurs amid a cluster pattern: 3 other insiders also bought within the past 14 days. While the company shows strong fundamentals—annual revenue growth of +53.4%, latest quarterly revenue of $8,899,000.00, and net income of $1,539,000.00—it was unprofitable over its most recent full fiscal year, creating a mixed signal between growth trajectory and profitability.

Director Gordon Gary B. buys 10,000 shares of TLSI at $2.46; stock down -61.9% from 52-week high, cluster of 4 other insider buys in past 14 days.

Director Gordon Gary B. purchased 10,000 shares at $2.46 on 2026-05-15, increasing his holdings to 72.5K shares (+16.0% vs pre-transaction holdings). The purchase occurs as the stock trades at $3.03, down -61.9% from its 52-week high of $7.95 and -34.8% over the past 30 days. His prior buy at TLSI on 2026-02-23 showed a 90d return of -34.6%, and across his cross-ticker track record, his 1 prior buy produced an avg 90d return of -34.6% with a 0.00% win rate, indicating a pattern of unfavorable post-purchase price performance. The filing also shows that 4 other insiders bought within the past 14 days, forming a cluster pattern. Against this backdrop, the company reported quarterly revenue of $8.9M and net income of $1.5M, with annual revenue growth of +53.4%, though full-year results were unprofitable and market cap stands at $186.1M.